Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VRK1 | Q99986 | 17/20 | 0.65 |
| ▸ | RPS6KA3 | P51812 | 5/20 | 0.65 |
| ▸ | VRK2 | Q86Y07 | 2/20 | 0.65 |
| ▸ | JAK2 | O60674 | 1/20 | 0.65 |
| ▸ | BRD4 | O60885 | 1/20 | 0.65 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.65 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.65 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.65 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13881333 | 0.79 | VRK1 (1.00) | VRK1RPS6KA3VRK2JAK2BRD4 | |
| SCHEMBL30013787 | 0.79 | VRK1 (1.00) | VRK1RPS6KA3VRK2JAK2BRD4 | |
| SCHEMBL28395290 | 0.73 | VRK1 (0.69) | VRK1RPS6KA3VRK2JAK2BRD4 | |
| SCHEMBL23252198 | 0.70 | VRK1 (0.65) | VRK1RPS6KA3VRK2JAK2BRD4 | |
| SCHEMBL17780349 | 0.69 | VRK1 (0.68) | VRK1RPS6KA3VRK2JAK2BRD4 | |
| SCHEMBL23828194 | 0.69 | RPS6KA6 (0.60) | VRK1RPS6KA3VRK2JAK2BRD4 | |
| SCHEMBL23828196 | 0.69 | RPS6KA6 (0.60) | VRK1RPS6KA3VRK2JAK2BRD4 | |
| SCHEMBL17257955 | 0.68 | VRK1 (0.76) | VRK1RPS6KA3VRK2JAK2BRD4 | |
| SCHEMBL28680815 | 0.64 | RPS6KA3 (0.70) | VRK1RPS6KA3VRK2JAK2BRD4 | |
| SCHEMBL25015531 | 0.62 | RPS6KA3 (1.00) | VRK1RPS6KA3VRK2JAK2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190314374-A1 | CALMODULIN INHIBITORS, CHK2 INHIBITORS AND RSK INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314374-A1 | CALMODULIN INHIBITORS, CHK2 INHIBITORS AND RSK INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES | RPS6KA1, RPS6KA2, RPS6KA6 | VRK1 405/4885RPS6KA3 4/4885VRK2 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.